Search results
Showing 251 to 300 of 7996 results
NICE has been collaborating with NHS England on the Chemotherapy Dose Standardisation initiative which has been developed by the Medicines...
There are 2 different points of the lifecycle of a NICE Technology Appraisal at which consideration of reference to or inclusion of a biosimilar is...
Biosimilar technologies: NICE position statement - information for the public
Biosimilar medicines – NICE's approach A biological medicine is any medicinal product made by or derived from a biological (natural) source, for...
We work with organisations to help to put our guidance into practice. We work with NHS, local authority and other organisations in their area,...
Patients taking part in clinical trials may receive drugs which have been evaluated by NICE technology appraisal guidance. Queries have been raised...
On this page, you'll find all our position statements relating to technology appraisals. Biosimilar technologies: NICE position statement Biosimilar
Tools and resources to help you implement guidance and quality standards at work.
Digitally enabled therapies for adults with depression: early value assessment (HTE8)
Early value assessment (EVA) guidance on digitally enabled therapies for adults with depression....
NICE transparency of spend
Join Nice's Public Involvement Programme expert panel
Role and responsibilities of the National Institute of Health and Care Excellence
The Office for Digital Health strives to accelerate NICE's efforts to deliver innovation to the health and care system.
The appeal panel is drawn from a group of people approved by the Secretary of State for Health and Social Care to hear appeals. Read the appeal panel
NICE guidance accredited decisions - status and term dates of NICE accredited guidance producers.
NICE committee vacancies for health, social care and other professionals and practitioners
We're looking for health, social care and other professionals and practitioners to take an active role in producing a NICE guideline or quality standard.
NICE committee vacancies for patients, service users, carers and lay people
// Return to the our committees home page .
The resources in this section have been developed to help you deliver services to your users. Buy books, journals and databases Use the NICE...
The NICE Electronic and Print Content Framework Agreement - enables the NHS and other health and social care related organisations to buy medical and healthcare related content.
We're looking for healthcare professionals and lay people to chair our guideline committees.
Evidence-based recommendations on belumosudil (Rezurock) for chronic graft-versus-host disease in people 12 years and over after 2 or more systemic treatments.
Evidence-based recommendations on nivolumab–relatlimab (Opdualag) for untreated advanced (unresectable or metastatic) melanoma in people 12 years and over.
Olaparib with abiraterone for untreated hormone-relapsed metastatic prostate cancer (TA951)
Evidence-based recommendations on olaparib (Lynparza) with abiraterone for untreated hormone-relapsed metastatic prostate cancer in adults.
A quick, easy way to access key information from NICE on social care topics.
We're developing a new centralised approach to prioritising our guidance topics. This will ensure that we produce guidance that is relevant, timely,...
Biographies and registered interests for members of the Technology Appraisal Committee A
Our role in the Innovative Licensing and Access Pathway (ILAP)
The Innovative Licensing and Access Pathway (ILAP) aims to streamline patient access to safe, financially sustainable and innovative medicines.
NICE Advice is an advisory service for pharmaceutical and healthtech companies seeking to enter the NHS market, and supporting organisations who fund or generate evidence for health technologies.
Evidence-based recommendations on loncastuximab tesirine (Zynlonta) for treating relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma in adults after 2 or more systemic treatments.
Evidence-based recommendations on ivosidenib (Tibsovo) for treating locally advanced or metastatic cholangiocarcinoma with an IDH1 R132 mutation in adults after 1 or more systemic treatments.
How to submit a new medical technology to NICE for guidance
Our medical technologies guidance evaluates new, innovative medical devices and diagnostics.
NICE is unable to make a recommendation on treosulfan (Trecondi) with fludarabine before allogeneic stem cell transplant for babies, children and young people aged 1 month to 17 years with non-malignant diseases. This is because Medac Pharma did not provide an evidence submission. We will review this decision if the company decides to make a submission.
Show all sections
Sections for TA945
This guideline covers when to offer and discuss caesarean birth, procedural aspects of the operation, and care after caesarean birth. It aims to improve the consistency and quality of care for women and pregnant people who are thinking about having a caesarean birth or have had a caesarean birth in the past and are now pregnant again.
An advisory service from the UK’s National Institute for Health and Care Excellence to help other countries improve their nation’s health and wellbeing
CKS end user licence agreement
In April 2021, the National Institute for Health Research (NIHR) launched a new rolling funding call for studies addressing NICE research recommendations.
How NICE manages the potential conflicts of interests of patient experts
People with lived experience provide valuable insight into the impact of NICE’s’ guidance and advice.
To support use of up-to-date content, and drive sustainability and digital transformation, the upcoming editions of BNF and BNFC (scheduled for distribution in October and November 2023) will be the last print editions to be supplied to the NHS in England by NICE.
Dr Sam Roberts, chief executive of NICE, celebrates the NHS on its 75th anniversary. She discusses how NICE has supported the NHS with its recent achievements. She also highlights how NICE is evolving; through driving value-based healthcare to support the NHS as it adapts to meet current challenges.
To mark Time to Talk Day (February 2) we spoke with Catherine Ruane, who acted as a carer for her father and sister, who both lived with depression.
Working at the forefront of neurodegenerative disease research
Claire Hawksworth reveals NICE’s role in a global partnership to better understand neurodegenerative conditions and speed up delivery of innovative treatments.
Pilar Pinilla-Dominguez reveals how NICE, through its international collaborations and partnerships, aims to contribute to improvements in health and care outcomes across the world, bringing learnings and benefits back to NICE, the NHS and the wider UK health and care system.
Increasing the capacity of our technology appraisals - the proportionate way
Jenniffer Prescott describes how we are trialling a proportionate approach to technology appraisals, which we expect will increase our capacity by 20% from 2023/24.
Using our guidance and resources in continuing professional development (CPD)
Registered social workers must demonstrate the use of evidence and research to inform their practice in order to meet professional standards. This is echoed in Social Work England’s continuing professional development (CPD) standards.
How is NICE supporting digital health technology developers?
Richard Chivers, operations manager for NICE Scientific Advice, looks at how we’re supporting digital health technology developers and helping them with some of the challenges around evidence requirements and adoption within the NHS.
Harriet Unsworth outlines her role in updating our evidence standards framework for digital health technologies. She also explains how you can share your views as part of our consultation.
Find out more about the diagnostics advisory committee members by reading their biographies. Dr Brian Shine (chair) Biography Brian is a
How NICE is helping to build the role of the NHS on the global stage
Kevin Miles discusses how NICE International is working to shape and improve health and care systems at home and abroad as part of the NHS Consortium for Global Health.
As we launch an early version of the online service, mapping out the regulatory and health technology assessment pathway, Ciara Cook invites future users to help shape this exciting new initiative.
NICE has launched a free learning course that provides an introduction to health technology assessment (HTA).